ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
Teva Pharma opens $110M plant in Hungary | Fierce Pharma